Trial Profile

A Phase I Trial of CRD3874-SI, a STING Agonist, in Patients With Advanced/Metastatic Malignant Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CRD 3874 (Primary)
Indications Haemangiosarcoma; Malignant fibrous histiocytoma; Merkel cell carcinoma; Osteosarcoma; Sarcoma; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology
27 Feb 2024 According to a Curadev Pharma media release, the dosing of patients with advanced sarcoma and Merkel cell carcinoma has been initiated at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. The first 4-week treatment cycle for the first patient is complete without adverse events.
04 Sep 2023 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com